Key Points Canopy Growth prioritizes profitability over pure revenue growth, which is evident in its divestitures and focus on higher-margin segments like medical cannabis and vaporizers. While the Canadian market presents challenges, international markets are driving significant revenue gains for the company. Acquisitions and strategic restructuring will allow Canopy Growth to capitalize on potential US federal legalization, though the timeline remains uncertain. 5 stocks we like better than Canopy Growth ...

财务数据和关键指标变化 - 第四季度合并净收入为7300万加元,同比增长16% [14] - 全年毛利率为27%,现金毛利率为35% [14] - 第四季度调整后EBITDA亏损1500万加元,同比改善63% [14] - 第四季度自由现金流流出2300万加元,同比改善75% [14] 各条业务线数据和关键指标变化 - 加拿大业务第四季度收入3700万加元,同比增长4% [15] - 加拿大医疗业务收入同比增长16% [15] - 加拿大成人用途B2B业务收入同比下降4% [15] - 加拿大业务第四季度毛利率为0%,现金毛利率为13% [16] - 国际市场业务第四季度收入同比增长32% [17] - Storz & Bickel第四季度收入同比增长43% [17] 各个市场数据和关键指标变化 - 波兰业务第四季度实现三位数增长 [17] - 德国业务第四季度实现双位数增长 [17] - 澳大利亚Storz & Bickel设备销售下降 [17] 公司战略和发展方向及行业竞争 - 公司实施资产轻型模式,专注核心优势并利用第三方扩大产能 [4] - 公司出售非大麻业务,全面聚焦大麻业务 [4] - 公司在加拿大、国际市场和Storz & Bickel业务均有良好表现 [5][6][7] - 公司加强财务状况,通过多项措施减少超过11亿加元债务 [6][19][20] - 公司计划在加拿大、国际市场和Storz & Bickel业务实现良好增长 [8][21] - 公司在美国市场通过Canopy USA战略加快布局 [11][12] - 预计大麻合法化将为公司带来重大机遇 [12] 管理层对经营环境和未来前景的评论 - 公司认为大麻是最令人兴奋的消费趋势之一 [4] - 公司对未来一年的表现充满信心,认为将是公司最好的一年 [7][13] - 公司认为加拿大市场、国际市场和Storz & Bickel业务均有良好增长前景 [8][21] - 公司对Canopy USA战略前景充满信心,认为将带来加速增长 [11][12] - 公司认为大麻合法化是行业的重大进步 [12] 其他重要信息 - 公司已实现2.8亿加元的累计成本节约,并计划在2025财年实现额外1000万至5000万加元的成本节约 [18] - 公司通过多项交易进一步改善财务状况,包括偿还短期债务、延长债务期限等 [19][20] 问答环节重要的提问和回答 问题1 **Aaron Grey 提问** 询问加拿大业务毛利率改善的时间节奏 [23] **Judy Hong 回答** 预计加拿大业务现金毛利率将在下半年达到中高30%水平,全年中高30%左右 [24] 问题2 **John Zamparo 提问** 询问公司如何看待剩余债务及偿还计划 [26] **Judy Hong 回答** 公司已消除短期债务,下一笔大额债务到期在2026年3月,公司有灵活性投资增长机会 [28] 问题3 **Yewon Kang 提问** 询问公司国际业务中美国CBD业务的情况 [30] **Judy Hong 回答** 公司正在将美国CBD业务转移至Canopy USA,未来不会再是Canopy的重点业务 [31]

Canopy Growth Corporation (CGC) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $2.30 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 15.15%. A quarter ago, it was expected that this company would post a loss of $0.45 per share when it actually produced a loss of $1.79, delivering a surprise of -297.78%. Over the last four quarters, the company ...

Exhibit 99.1 Canopy Growth Reports Fourth Quarter and Fiscal Year 2024 Financial Results; Q4 FY2024 Net Revenue increased 7% year-over-year, or 16% excluding divested businesses Storz & Bickel® delivered its best Q4 revenue quarter, with net revenue increasing 43% as compared to Q4 2023 Canada medical cannabis net revenue increased 16% in Q4 FY2024 and 10% in FY2024 year-over-year Canada cannabis Cost of Goods Sold decreased by 54% in FY2024 versus FY2023 Following recent balance sheet actions, the Company ...

Storz & Bickel® delivered its best Q4 revenue quarter, with net revenue increasing 43% as compared to Q4 2023 Canada medical cannabis net revenue increased 16% in Q4 FY2024 and 10% in FY2024 year-over-year Canada cannabis Cost of Goods Sold decreased by 54% in FY2024 versus FY2023 Following recent balance sheet actions, the Company has no material debt obligation due until March 20261 SMITHS FALLS, ON, May 30, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy", "Canopy Growth" or the "Company") (TSX: W ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38496 Canopy Growth Corporation (Exact name of registrant as specified in its charter) Canada N/A (State or other jurisdiction of (I.R.S ...

Canopy Growth Corporation (CGC) is scheduled to report fourth-quarter fiscal 2024 results on May 30 before the opening bell. Let’s consider a few factors that might have influenced this cannabis major’s results in this to-be-reported quarter. However, it’s worth examining CGC’s performance in the previous quarter first. Surprising History and Estimates at a Glance In the third quarter of fiscal 2024, the company reported a loss of $1.79 compared with the Zacks Consensus Estimate of a loss of 45 cents per sh ...

Canopy Growth Corporation (CGC) closed the most recent trading day at $9.18, moving +0.77% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.7%. Elsewhere, the Dow gained 0.01%, while the tech-heavy Nasdaq added 1.1%. The company's stock has climbed by 4.71% in the past month, exceeding the Medical sector's gain of 3.27% and the S&P 500's gain of 4.03%. Market participants will be closely following the financial results of Canopy Growth Corporation in its upcoming release. ...

Canopy Growth Corporation (CGC) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released o ...

In the latest market close, Canopy Growth Corporation (CGC) reached $10.85, with a -1.36% movement compared to the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.12%. At the same time, the Dow added 0.34%, and the tech-heavy Nasdaq lost 0.07%. Shares of the company witnessed a gain of 40.49% over the previous month, beating the performance of the Medical sector with its gain of 5.73% and the S&P 500's gain of 4.99%. The investment community will be paying close attention to ...